Vai trò của Matrix Metalloproteinases và lợi ích điều trị của việc ức chế chúng trong chấn thương tủy sống

Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007;8:221–233. Yong VW. Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci 2005;6:931–944. Yong VW, Agrawal SM, Stirling DP. Targeting MMPs in acute and chronic neurological conditions. Neurotherapeutics 2007;4:580–589. Zhang H, Adwanikar H, Werb Z, Noble-Haeusslein LJ. Matrix metalloproteinases and neurotrauma: evolving roles in injury and reparative processes. Neuroscientist 2010;16:156–170. Noble LJ, Donovan F, Igarashi T, Goussev S, Werb Z. Matrix metalloproteinases limit functional recovery after spinal cord injury by modulation of early vascular events. J Neurosci 2002;22:7526–7535. Yu F, Kamada H, Niizuma K, Endo H, Chan PH. Induction of mmp-9 expression and endothelial injury by oxidative stress after spinal cord injury. J Neurotrauma 2008;25:184–195. Rosell A, Lo EH. Multiphasic roles for matrix metalloproteinases after stroke. Curr Opin Pharmacol 2008;8:82–89. Agrawal SM, Lau L, Yong VW. MMPs in the central nervous system: where the good guys go bad. Semin Cell Dev Biol 2008;19:42–51. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463–516. Imai K, Yokohama Y, Nakanishi I, et al. Matrix metalloproteinase 7 [matrilysin] from human rectal carcinoma cells. Activation of the precursor, interaction with other matrix metalloproteinases and enzymic properties. J Biol Chem 1995;270:6691–6697. Knauper V, Bailey L, Worley JR, Soloway P, Patterson ML, Murphy G. Cellular activation of proMMP-13 by MT1-MMP depends on the C-terminal domain of MMP-13. FEBS Lett 2002;532:127–130. Cowell S, Knauper V, Stewart ML, et al. Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase: associated activation of gelatinase A, gelatinase B and collagenase 3. Biochem J 1998;331(pt 2):453–458. Crocker SJ, Pagenstecher A, Campbell IL. The TIMPs tango with MMPs and more in the central nervous system. J Neurosci Res 2004;75:1–11. de Castro RC Jr., Burns CL, McAdoo DJ, Romanic AM. Metalloproteinase increases in the injured rat spinal cord. Neuroreport 2000;11:3551–3554. Duchossoy Y, Horvat JC, Stettler O. MMP-related gelatinase activity is strongly induced in scar tissue of injured adult spinal cord and forms pathways for ingrowing neurites. Mol Cell Neurosci 2001;17:945–956. Goussev S, Hsu JY, Lin Y, et al. Differential temporal expression of matrix metalloproteinases after spinal cord injury: relationship to revascularization and wound healing. J Neurosurg 2003;99:188–197. Hsu JY, McKeon R, Goussev S, et al. Matrix metalloproteinase-2 facilitates wound healing events that promote functional recovery after spinal cord injury. J Neurosci 2006;26:9841–9850. Xu J, Kim GM, Ahmed SH, Yan P, Xu XM, Hsu CY. Glucocorticoid receptor-mediated suppression of activator protein-1 activation and matrix metalloproteinase expression after spinal cord injury. J Neurosci 2001;21:92–97. Wells JE, Rice TK, Nuttall RK, et al. An adverse role for matrix metalloproteinase 12 after spinal cord injury in mice. J Neurosci 2003;23:10107–10115. Veeravalli KK, Dasari VR, Tsung AJ, et al. Human umbilical cord blood stem cells upregulate matrix metalloproteinase-2 in rats after spinal cord injury. Neurobiol Dis 2009;36:200–212. Yang Y, Estrada EY, Thompson JF, Liu W, Rosenberg GA. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 2007;27:697–709. Buhler LA, Samara R, Guzman E, et al. Matrix metalloproteinase-7 facilitates immune access to the CNS in experimental autoimmune encephalomyelitis. BMC Neurosci 2009;10:17. Asahi M, Wang X, Mori T, et al. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 2001;21:7724–7732. Caron A, Desrosiers RR, Beliveau R. Ischemia injury alters endothelial cell properties of kidney cortex: stimulation of MMP-9. Exp Cell Res 2005;310:105–116. Rosenberg GA, Yang Y. Vasogenic edema due to tight junction disruption by matrix metalloproteinases in cerebral ischemia. Neurosurg Focus 2007;22:E4. Reijerkerk A, Kooij G, van der Pol SM, Khazen S, Dijkstra CD, de Vries HE. Diapedesis of monocytes is associated with MMP-mediated occludin disappearance in brain endothelial cells. FASEB J 2006;20:2550–2552. Whetstone WD, Hsu JY, Eisenberg M, Werb Z, Noble-Haeusslein LJ. Blood-spinal cord barrier after spinal cord injury: relation to revascularization and wound healing. J Neurosci Res 2003;74:227–239. Shipley JM, Wesselschmidt RL, Kobayashi DK, Ley TJ, Shapiro SD. Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc Natl Acad Sci U S A 1996;93:3942–3946. Haorah J, Ramirez SH, Schall K, Smith D, Pandya R, Persidsky Y. Oxidative stress activates protein tyrosine kinase and matrix metalloproteinases leading to blood-brain barrier dysfunction. J Neurochem 2007;101:566–576. Alexander JS, Elrod JW. Extracellular matrix, junctional integrity and matrix metalloproteinase interactions in endothelial permeability regulation. J Anat 2002;200:561–574. Sugawara T, Lewen A, Gasche Y, Yu F, Chan PH. Overexpression of SOD1 protects vulnerable motor neurons after spinal cord injury by attenuating mitochondrial cytochrome c release. FASEB J 2002;16:1997–1999. Dang AB, Tay BK, Kim HT, Nauth A, Alfonso-Jaume MA, Lovett DH. Inhibition of MMP2/MMP9 after spinal cord trauma reduces apoptosis. Spine [Phila Pa 1976] 2008;33:E576-579. Trivedi A, Hsu CY, Lin Y, et al. The effects of acute and extended inhibition of matrix metalloproteinases on demyelination and functional recovery after spinal cord injury. Int J Neuroprotect Neuroregen 2005;2:30–38. Pizzi MA, Crowe MJ. Matrix metalloproteinases and proteoglycans in axonal regeneration. Exp Neurol 2007;204:496–511. Silver J, Miller JH. Regeneration beyond the glial scar. Nat Rev Neurosci 2004;5:146–156. Jones LL, Yamaguchi Y, Stallcup WB, Tuszynski MH. NG2 is a major chondroitin sulfate proteoglycan produced after spinal cord injury and is expressed by macrophages and oligodendrocyte progenitors. J Neurosci 2002;22:2792–2803. Bradbury EJ, Moon LD, Popat RJ, et al. Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature 2002;416:636–640. Hsu JY, Bourguignon LY, Adams CM, et al. Matrix metalloproteinase-9 facilitates glial scar formation in the injured spinal cord. J Neurosci 2008;28:13467–13477. Busch SA, Horn KP, Silver DJ, Silver J. Overcoming macrophage-mediated axonal dieback following CNS injury. J Neurosci 2009;29:9967–9976. Yong VW, Power C, Forsyth P, Edwards DR. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2001;2:502–511. Siddall PJ, McClelland JM, Rutkowski SB, Cousins MJ. A longitudinal study of the prevalence and characteristics of pain in the first 5 years following spinal cord injury. Pain 2003;103:249–257. Detloff MR, Fisher LC, McGaughy V, Longbrake EE, Popovich PG, Basso DM. Remote activation of microglia and pro-inflammatory cytokines predict the onset and severity of below-level neuropathic pain after spinal cord injury in rats. Exp Neurol 2008;212:337–347. Kawasaki Y, Xu ZZ, Wang X, et al. Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain. Nat Med 2008;14:331–336. Kobayashi H, Chattopadhyay S, Kato K, et al. MMPs initiate Schwann cell-mediated MBP degradation and mechanical nociception after nerve damage. Mol Cell Neurosci 2008;39:619–627. Chattopadhyay S, Myers RR, Janes J, Shubayev V. Cytokine regulation of MMP-9 in peripheral glia: implications for pathological processes and pain in injured nerve. Brain Behav Immun 2007;21:561–568. Chandler S, Coates R, Gearing A, Lury J, Wells G, Bone E. Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett 1995;201:223–226. Devor M. Sodium channels and mechanisms of neuropathic pain. J Pain 2006;7:S3-S12. Schafers M, Sorkin L. Effect of cytokines on neuronal excitability. Neurosci Lett 2008;437:188–193. Overall CM, Kleifeld O. Tumour microenvironment — opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006;6:227–239. Fisher JF, Mobashery S. Recent advances in MMP inhibitor design. Cancer Metastasis Rev 2006;25:115–136. Jacobsen JA, Major Jourden JL, Miller MT, Cohen SM. To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition. Biochim Biophys Acta 2010;1803:72–94. Dorman G, Cseh S, Hajdu I, et al. Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility. Drugs 2010;70:949–964. Peterson JT. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev 2004;9:63–79. Wada CK, Holms JH, Curtin ML, et al. Phenoxyphenyl sulfone N-formylhydroxylamines [retrohydroxamates] as potent, selective, orally bioavailable matrix metalloproteinase inhibitors. J Med Chem 2002;45:219–232. Ishikawa T, Nishigaki F, Miyata S, et al. Prevention of progressive joint destruction in collagen-induced arthritis in rats by a novel matrix metalloproteinase inhibitor, FR255031. Br J Pharmacol 2005;144:133–143. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006;54:258–265. Romero-Perez D, Fricovsky E, Yamasaki KG, et al. Cardiac uptake of minocycline and mechanisms for in vivo cardioprotection. J Am Coll Cardiol 2008;52:1086–1094. Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM. The promise of minocycline in neurology. Lancet Neurol 2004;3:744–751. Kim HS, Suh YH. Minocycline and neurodegenerative diseases. Behav Brain Res 2009;196:168–179. Lee HM, Golub LM, Cao J, et al. CMT-3, a non-antimicrobial tetracycline [TC], inhibits MT1-MMP activity: relevance to cancer. Curr Med Chem 2001;8:257–260. Teronen O, Heikkila P, Konttinen YT, et al. MMP inhibition and downregulation by bisphosphonates. Ann N Y Acad Sci 1999;878:453–465. Heikkila P, Teronen O, Moilanen M, et al. Bisphosphonates inhibit stromelysin-1 [MMP-3], matrix metalloelastase [MMP-12], collagenase-3 [MMP-13] and enamelysin [MMP-20], but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. Anticancer Drugs 2002;13:245–254. Boissier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000;60:2949–2954. Hoffman A, Qadri B, Frant J, et al. Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis. J Med Chem 2008;51:1406–1414. Matziari M, Beau F, Cuniasse P, Dive V, Yiotakis A. Evaluation of P1'-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11. J Med Chem 2004;47:325–336. Reiter LA, Mitchell PG, Martinelli GJ, Lopresti-Morrow LL, Yocum SA, Eskra JD. Phosphinic acid-based MMP-13 inhibitors that spare MMP-1 and MMP-3. Bioorg Med Chem Lett 2003;13:2331–2336. Brown S, Bernardo MM, Li ZH, et al. Potent and selective mechanism-based inhibition of gelatinases. J Am Chem Soc 2000;122:6799–6800. Toth M, Bernardo MM, Gervasi DC, et al. Tissue inhibitor of metalloproteinase [TIMP]-2 acts synergistically with synthetic matrix metalloproteinase [MMP] inhibitors but not with TIMP-4 to enhance the [membrane type 1]-MMP-dependent activation of pro-MMP-2. J Biol Chem 2000;275:41415–41423. Forbes C, Shi Q, Fisher JF, et al. Active site ring-opening of a thiirane moiety and picomolar inhibition of gelatinases. Chem Biol Drug Des 2009;74:527–534. Gu Z, Cui J, Brown S, et al. A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci 2005;25:6401–6408. Luplertlop N, Misse D, Bray D, et al. Dengue-virus-infected dendritic cells trigger vascular leakage through metalloproteinase overproduction. EMBO Rep 2006;7:1176–1181. Ota R, Kurihara C, Tsou TL, et al. Roles of matrix metalloproteinases in flow-induced outward vascular remodeling. J Cereb Blood Flow Metab 2009;29:1547–1558. Guo Z, Sun X, He Z, Jiang Y, Zhang X, Zhang JH. Matrix metalloproteinase-9 potentiates early brain injury after subarachnoid hemorrhage. Neurol Res 2010;32:715–720. He ZJ, Huang ZT, Chen XT, Zou ZJ. Effects of matrix metalloproteinase 9 inhibition on the blood brain barrier and inflammation in rats following cardiopulmonary resuscitation. Chin Med J [Engl] 2009;122:2346–2351. Lee M, Villegas-Estrada A, Celenza G, et al. Metabolism of a highly selective gelatinase inhibitor generates active metabolite. Chem Biol Drug Des 2007;70:371–382. Lee M, Celenza G, Boggess B, et al. A potent gelatinase inhibitor with anti-tumor-invasive activity and its metabolic disposition. Chem Biol Drug Des 2009;73:189–202. Testero SA, Lee M, Staran R, et al. Sulfonate-containing thiiranes as selective gelatinase inhibitors. Med Chem Lett 2011;2:177–181. Ikejiri M, Bernardo MM, Meroueh SO, et al. Design, synthesis, and evaluation of a mechanism-based inhibitor for gelatinase A. J Org Chem 2005;70:5709–5712. Gooyit M, Lee M, Hesek D, et al. Synthesis, kinetic characterization and metabolism of diastereomeric 2-[1-[4-phenoxyphenylsulfonyl]ethyl]thiiranes as potent gelatinase and MT1-MMP inhibitors. Chem Biol Drug Des 2009;74:535–546. Botos I, Scapozza L, Zhang D, Liotta LA, Meyer EF. Batimastat, a potent matrix mealloproteinase inhibitor, exhibits an unexpected mode of binding. Proc Natl Acad Sci U S A 1996;93:2749–2754. Grobelny D, Poncz L, Galardy RE. Inhibition of human skin fibroblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acids. Biochemistry 1992;31:7152–7154. Naglich JG, Jure-Kunkel M, Gupta E, et al. Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Res 2001;61:8480–8485. Gatto C, Rieppi M, Borsotti P, et al. BAY 12–9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity. Clin Cancer Res 1999;5:3603–3607. Aranapakam V, Grosu GT, Davis JM, et al. Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis. J Med Chem 2003;46:2361–2375. Tamura Y, Watanabe F, Nakatani T, et al. Highly selective and orally active inhibitors of type IV collagenase [MMP-9 and MMP-2]: N-sulfonylamino acid derivatives. J Med Chem 1998;41:640–649. Aoki T, Kataoka H, Morimoto M, Nozaki K, Hashimoto N. Macrophage-derived matrix metalloproteinase-2 and −9 promote the progression of cerebral aneurysms in rats. Stroke 2007;38:162–169. Becker DP, Barta TE, Bedell LJ, et al. Orally active MMP-1 sparing alpha-tetrahydropyranyl and alpha-piperidinyl sulfone matrix metalloproteinase [MMP] inhibitors with efficacy in cancer, arthritis, and cardiovascular disease. J Med Chem 2010;53:6653–6680. Kolodziej SA, Hockerman SL, Boehm TL, et al. Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates. Bioorg Med Chem Lett 2010;20:3557–3560. Nelson FC, Delos Santos E, Levin JI, et al. Benzodiazepine inhibitors of the MMPs and TACE. Bioorg Med Chem Lett 2002;12:2867–2870. Yang SM, Scannevin RH, Wang B, et al. beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents. Bioorg Med Chem Lett 2008;18:1140–1145. Curtin ML, Florjancic AS, Heyman HR, et al. Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770. Bioorg Med Chem Lett 2001;11:1557–1560. Chung YJ, Lee KH, Park SH, Cho CW, Han MS. 5-carboxylate substituted piperazine-2-ones as potent and selective MMP-2 inhibitors. Bull Korean Chem Soc 2008;29:1103–1104. Maquoi E, Sounni NE, Devy L, et al. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor. Clin Cancer Res 2004;10:4038–4047. Kim SH, Pudzianowski AT, Leavitt KJ, et al. Structure-based design of potent and selective inhibitors of collagenase-3 [MMP-13]. Bioorg Med Chem Lett 2005;15:1101–1106. Levin JI, Du MT, DiJoseph JF, et al. The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position. Bioorg Med Chem Lett 2001;11:235–238. Levin JI, Gu Y, Nelson FC, et al. Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases. Bioorg Med Chem Lett 2001;11:239–242. Zhang L, Zhang J, Fang H, Wang Q, Xu W. Design, synthesis and preliminary evaluation of new cinnamoyl pyrrolidine derivatives as potent gelatinase inhibitors. Bioorg Med Chem 2006;14:8286–8294. Cheng XC, Wang Q, Fang H, Tang W, Xu WF. Design, synthesis and evaluation of novel sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors. Bioorg Med Chem 2008;16:5398–5404. Lokeshwar BL, Selzer MG, Zhu BQ, Block NL, Golub LM. Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog [COL-3] in a metastatic prostate cancer model. Int J Cancer 2002;98:297–309. Lee M, Bernardo MM, Meroueh SO, Brown S, Fridman R, Mobashery S. Synthesis of chiral 2-[4-phenoxyphenylsulfonylmethyl]thiiranes as selective gelatinase inhibitors. Org Lett 2005;7:4463–4465.